Antituberculosis therapy and current global guidelines

Giovanni Battista Migliori, Giovanni Sotgiu, Rosella Centis, Malgorzata Grzemska, Dennis Falzon, Haileyesus Getahun, Mario C. Raviglione

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The WHO Stop-TB Strategy has dramatically improved the control of TB worldwide. The emergence and the spread of anti-TB drug resistance can be prevented by the prescription of an effective anti-TB therapy. Drug sensitivity testing results are helpful to identify the most effective anti-TB drugs. WHO recommends to treat new TB cases for 6 months (H, R, Z, and E for 2 months, and H and R for other 4 months). WHO recommends to prescribe ART in all TB/HIV coinfected individuals (within the first 2 months after the start of the anti-TB therapy). Clinical management of adverse events due to anti-TB drugs increases the probability of treatment success.

Original languageEnglish
Title of host publicationCurrent and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis
PublisherFuture Medicine Ltd.
Pages43-63
Number of pages21
ISBN (Print)9781780840222, 9781780841113
DOIs
Publication statusPublished - Oct 1 2011

Fingerprint

Guidelines
Pharmaceutical Preparations
Drug Resistance
Prescriptions
Therapeutics
HIV
R 4 H

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Migliori, G. B., Sotgiu, G., Centis, R., Grzemska, M., Falzon, D., Getahun, H., & Raviglione, M. C. (2011). Antituberculosis therapy and current global guidelines. In Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis (pp. 43-63). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.56

Antituberculosis therapy and current global guidelines. / Migliori, Giovanni Battista; Sotgiu, Giovanni; Centis, Rosella; Grzemska, Malgorzata; Falzon, Dennis; Getahun, Haileyesus; Raviglione, Mario C.

Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis. Future Medicine Ltd., 2011. p. 43-63.

Research output: Chapter in Book/Report/Conference proceedingChapter

Migliori, GB, Sotgiu, G, Centis, R, Grzemska, M, Falzon, D, Getahun, H & Raviglione, MC 2011, Antituberculosis therapy and current global guidelines. in Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis. Future Medicine Ltd., pp. 43-63. https://doi.org/10.2217/EBO.11.56
Migliori GB, Sotgiu G, Centis R, Grzemska M, Falzon D, Getahun H et al. Antituberculosis therapy and current global guidelines. In Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis. Future Medicine Ltd. 2011. p. 43-63 https://doi.org/10.2217/EBO.11.56
Migliori, Giovanni Battista ; Sotgiu, Giovanni ; Centis, Rosella ; Grzemska, Malgorzata ; Falzon, Dennis ; Getahun, Haileyesus ; Raviglione, Mario C. / Antituberculosis therapy and current global guidelines. Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis. Future Medicine Ltd., 2011. pp. 43-63
@inbook{8a87dbc6b4e04e5498c08d0483cdcd9a,
title = "Antituberculosis therapy and current global guidelines",
abstract = "The WHO Stop-TB Strategy has dramatically improved the control of TB worldwide. The emergence and the spread of anti-TB drug resistance can be prevented by the prescription of an effective anti-TB therapy. Drug sensitivity testing results are helpful to identify the most effective anti-TB drugs. WHO recommends to treat new TB cases for 6 months (H, R, Z, and E for 2 months, and H and R for other 4 months). WHO recommends to prescribe ART in all TB/HIV coinfected individuals (within the first 2 months after the start of the anti-TB therapy). Clinical management of adverse events due to anti-TB drugs increases the probability of treatment success.",
author = "Migliori, {Giovanni Battista} and Giovanni Sotgiu and Rosella Centis and Malgorzata Grzemska and Dennis Falzon and Haileyesus Getahun and Raviglione, {Mario C.}",
year = "2011",
month = "10",
day = "1",
doi = "10.2217/EBO.11.56",
language = "English",
isbn = "9781780840222",
pages = "43--63",
booktitle = "Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Antituberculosis therapy and current global guidelines

AU - Migliori, Giovanni Battista

AU - Sotgiu, Giovanni

AU - Centis, Rosella

AU - Grzemska, Malgorzata

AU - Falzon, Dennis

AU - Getahun, Haileyesus

AU - Raviglione, Mario C.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The WHO Stop-TB Strategy has dramatically improved the control of TB worldwide. The emergence and the spread of anti-TB drug resistance can be prevented by the prescription of an effective anti-TB therapy. Drug sensitivity testing results are helpful to identify the most effective anti-TB drugs. WHO recommends to treat new TB cases for 6 months (H, R, Z, and E for 2 months, and H and R for other 4 months). WHO recommends to prescribe ART in all TB/HIV coinfected individuals (within the first 2 months after the start of the anti-TB therapy). Clinical management of adverse events due to anti-TB drugs increases the probability of treatment success.

AB - The WHO Stop-TB Strategy has dramatically improved the control of TB worldwide. The emergence and the spread of anti-TB drug resistance can be prevented by the prescription of an effective anti-TB therapy. Drug sensitivity testing results are helpful to identify the most effective anti-TB drugs. WHO recommends to treat new TB cases for 6 months (H, R, Z, and E for 2 months, and H and R for other 4 months). WHO recommends to prescribe ART in all TB/HIV coinfected individuals (within the first 2 months after the start of the anti-TB therapy). Clinical management of adverse events due to anti-TB drugs increases the probability of treatment success.

UR - http://www.scopus.com/inward/record.url?scp=84956720650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956720650&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.56

DO - 10.2217/EBO.11.56

M3 - Chapter

AN - SCOPUS:84956720650

SN - 9781780840222

SN - 9781780841113

SP - 43

EP - 63

BT - Current and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis

PB - Future Medicine Ltd.

ER -